Moderna announced their bivalent coronavirus vaccine that targets both the original strain and Omicron has a strong immune response.
The bivalent vaccine had a neutralizing geometric mean titer ratio of 1.75 (97.5% CI of 1.49 to 2.04) compared to the original vaccine. And neutralizing geometric mean titers against Omicron were 8-fold above baseline.
The FDA's advisory committee VRBPAC is going to discuss updating the vaccine strain at the end of the month. I think this data will support an update. Pfizer also has an Omicron-specific vaccine, but it is monovalent. If an update is recommended, then the FDA's Peter Marks wants both companies to target similar strains.